Company Analysis
Sign in

Creative Medical Technology Holdings, Inc. (CELZ)

Nasdaq: CELZ · Biological Products, (No Diagnostic Substances) · Phoenix, AZ · filing with the SEC since 2002
Full chart Alerts Compare
Grade4.5
◀ Past 5.7● Present 5.0▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Creative Medical Technology Holdings, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.5/10
◀ Past5.725% of the headline
● Present5.035% of the headline
▶ Future3.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.0/10

Has it survived what it has been through?

6 warning events since 2017; the latest 2025-04-11.

weight 22% of this tense · 20th percentile among 159 sector filers · read for itself

From the record

Creative Medical Technology Holdings, Inc.'s filings since 2017 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2025-04-11); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2020-03-30) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
4.5/10

What has it actually done, year after year?

10 filed years; profitable in 1 of 10.

weight 45% of this tense · 45th percentile among 102 sector filers · read for its customers

From the record

Creative Medical Technology Holdings, Inc.'s 10 filed years say what it did: it rose in 4 of 8 years; the deepest fall was 96% from fiscal 2019 to fiscal 2025; net income was positive in 1 of 10 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 42% of its family
  • the share of filed years with a profittop 35% of its family
  • the deepest fall from a revenue peak96.4%bottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
9.8/10

How has it treated the people who own it?

SI estimate 9.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 98th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 2% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Creative Medical Technology Holdings, Inc.'s shareholder treatment is put at 9.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 2% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.0/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
4.2/10

Is it financially healthy right now?

ROE -80%: lost 80¢ per shareholder dollar. Leverage 4%: owes 4¢ per asset dollar.

weight 45% of this tense · 42nd percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Creative Medical Technology Holdings, Inc. lost about 80 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 4 cents per dollar of assets, and net share issuance: its share count grew 61.0% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 3% of its family
  • return on equitybottom 34% of its family
  • gross profit against assetsbottom 12% of its family
  • the share count against the year beforebottom 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.3/10

How strong is its position in its industry?

bottom 3% of 102 in its family; net margin -99916.8%.

weight 22% of this tense · 3rd percentile among 102 sector filers · read for its customers

From the record

Creative Medical Technology Holdings, Inc.'s standing among 102 graded names in its industry family: revenue of $6 thousand in fiscal 2025 ranks in the bottom 1% by size; a net margin of -99916.8% ranks in the bottom 2%; revenue growth of -59.2% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).

What it rests on

  • revenue against the family$6000.00bottom 1% of its family
  • net margin-99916.8%bottom 2% of its family
  • three-year revenue growth-59.2%bottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
9.2/10

What are the people in charge doing?

SI estimate 9.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 92nd percentile among 137 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the chief executive's years under the title, which ranks in the top 8% of 137 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
What the record cannot read
Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned
one part: the chief executive's years on the record, the one part on file, ranked among 137 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Creative Medical Technology Holdings, Inc.'s leadership is put at 9.2 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the top 8% of 137 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.4/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.9/10

How much room does it have to grow?

top 41% of 92 in its family for room to expand.

weight 33% of this tense · 59th percentile among 92 sector filers · read for itself

From the record

Creative Medical Technology Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 92.3% of its assets as net cash, top 6% of its family; cash from operations less capital spending is -97607.4% of revenue (bottom 2%); a gross margin of 63.4% (bottom 44%); research spending of 37663.3% of revenue (top 3%) (its annual report).

What it rests on

  • cash less debt against assets92.3%top 6% of its family
  • cash from operations less capital spending against revenue-97607.4%bottom 2% of its family
  • gross margin63.4%bottom 44% of its family
  • research spending against revenue37663.3%top 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
1.1/10

What could actually drive growth from here?

bottom 11% of 100 in its family for growth drivers.

weight 45% of this tense · 11th percentile among 100 sector filers · read for its customers

From the record

Creative Medical Technology Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew -45.5% (bottom 14%); research spending grew -28.8% a year (bottom 7%) (its annual reports). Creative Medical Technology Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth-45.5%bottom 14% of its family
  • three-year growth of research spending-28.8%bottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
4.3/10

Did its newest year beat what its own record pointed to?

bottom 43% of 72 in its family for expectations against reality.

weight 22% of this tense · 43rd percentile among 72 sector filers · read for its shareholders

From the record

Creative Medical Technology Holdings, Inc.'s newest year against its own record: revenue of $6 thousand in fiscal 2025 came in 54.7% above the $4 thousand its prior three years' pace pointed to (top 25% of its family); net income of $6 million against a prior three-year average of $7 million (top 49%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 2%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace54.7%top 25% of its family
  • net income against the prior three years' average+14%top 49% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CELZ · research, not advice